CU20170084A7 - COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC - Google Patents

COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC

Info

Publication number
CU20170084A7
CU20170084A7 CUP2017000084A CU20170084A CU20170084A7 CU 20170084 A7 CU20170084 A7 CU 20170084A7 CU P2017000084 A CUP2017000084 A CU P2017000084A CU 20170084 A CU20170084 A CU 20170084A CU 20170084 A7 CU20170084 A7 CU 20170084A7
Authority
CU
Cuba
Prior art keywords
compounds
isoxazol
acid compounds
hydroxamic acid
lpxc inhibitors
Prior art date
Application number
CUP2017000084A
Other languages
English (en)
Other versions
CU24443B1 (es
Inventor
Jiping Fu
Xianming Jin
Subramanian Karur
Guillaume Lapointe
Ann Marie Madera
Zachary Kevin Sweeney
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20170084A7 publication Critical patent/CU20170084A7/es
Publication of CU24443B1 publication Critical patent/CU24443B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>Esta invención se refiere en general a compuestos de Fórmula I tal como se describen en el presente documento y composiciones que contienen dichos compuestos, así como métodos de uso de dichos compuestos para tratar infecciones bacterianas. En ciertos aspectos, Ia invención proporciona métodos y composiciones que comprenden estos compuestos para el tratamiento de infecciones causadas por bacterias Gram negativas.</p> <p>ESPACIO PARA FÓRMULA<br />  </p>
CU2017000084A 2014-12-16 2015-12-15 COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC CU24443B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462092402P 2014-12-16 2014-12-16
PCT/IB2015/059631 WO2016097995A1 (en) 2014-12-16 2015-12-15 Isoxazole hydroxamic acid compounds as lpxc inhibitors

Publications (2)

Publication Number Publication Date
CU20170084A7 true CU20170084A7 (es) 2017-11-07
CU24443B1 CU24443B1 (es) 2019-10-04

Family

ID=55025302

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000084A CU24443B1 (es) 2014-12-16 2015-12-15 COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC

Country Status (41)

Country Link
US (3) US9549916B2 (es)
EP (1) EP3233843B1 (es)
JP (1) JP6697466B2 (es)
KR (1) KR20170094214A (es)
CN (1) CN107001295B (es)
AR (1) AR107428A1 (es)
AU (1) AU2015365455B2 (es)
BR (1) BR112017011422A2 (es)
CA (1) CA2969803A1 (es)
CL (1) CL2017001460A1 (es)
CO (1) CO2017005870A2 (es)
CR (1) CR20170260A (es)
CU (1) CU24443B1 (es)
CY (1) CY1122305T1 (es)
DK (1) DK3233843T3 (es)
EA (1) EA032138B1 (es)
EC (1) ECSP17045737A (es)
ES (1) ES2756300T3 (es)
GT (1) GT201700132A (es)
HR (1) HRP20192009T1 (es)
HU (1) HUE047225T2 (es)
IL (1) IL252373B (es)
JO (1) JO3818B1 (es)
LT (1) LT3233843T (es)
MA (1) MA41185B1 (es)
ME (1) ME03546B (es)
MX (1) MX2017007980A (es)
MY (1) MY195743A (es)
PE (1) PE20171044A1 (es)
PH (1) PH12017501019A1 (es)
PL (1) PL3233843T3 (es)
PT (1) PT3233843T (es)
RS (1) RS59507B1 (es)
SG (1) SG11201704053WA (es)
SI (1) SI3233843T1 (es)
SV (1) SV2017005462A (es)
TN (1) TN2017000207A1 (es)
TW (1) TWI693215B (es)
UA (1) UA121225C2 (es)
UY (1) UY36448A (es)
WO (1) WO2016097995A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200527A1 (es) 2013-05-17 2020-03-09 Incyte Corp Derivados del bipirazol como inhibidores jak
EA036243B1 (ru) * 2016-06-14 2020-10-16 Новартис Аг Кристаллическая форма (r)-4-(5-(циклопропилэтинил)изоксазол-3-ил)-n-гидрокси-2-метил-2-(метилсульфонил)бутанамида как антибактериальное средство
CN107434766A (zh) * 2017-08-09 2017-12-05 凯莱英医药集团（天津）股份有限公司 烷烃羟胺类化合物的合成装置及连续合成方法
BR122023022189A2 (pt) 2018-02-16 2024-02-20 Incyte Corporation Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
CA3119957A1 (en) * 2018-11-21 2020-05-28 Taisho Pharmaceutical Co., Ltd. Novel imidazole derivative
CA3184275A1 (en) 2020-06-02 2021-12-09 Incyte Corporation Processes of preparing a jak1 inhibitor
EP4259131A1 (en) 2020-12-08 2023-10-18 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN112603936B (zh) * 2020-12-28 2022-08-02 仲恺农业工程学院 一种抑制气单胞菌属的组合物及其制备方法与应用
EP4291550A1 (en) * 2021-02-11 2023-12-20 Blacksmith Medicines, Inc. Antibacterial compounds
CN117279898A (zh) * 2021-02-11 2023-12-22 布莱克史密斯医药公司 抗菌化合物
CA3233328A1 (en) * 2021-09-28 2023-04-06 Min Teng Lpxc inhibitors and uses thereof
WO2024067813A1 (zh) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和其医药上的用途
WO2024067812A1 (zh) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
DE59009528D1 (de) 1989-09-22 1995-09-21 Basf Ag Carbonsäureamide.
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
AU1102399A (en) 1997-10-21 1999-05-10 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
DK1196186T3 (da) 1999-07-12 2008-03-03 Genentech Inc Stimulering eller inhibering af angiogenese og kardiovaskularisation med tumornekrosefaktorligand/receptorhomologer
MXPA05006828A (es) 2002-12-23 2005-09-08 Wyeth Corp Anticuerpos contra pd-1, y sus usos.
EA011808B1 (ru) * 2003-01-08 2009-06-30 Новартис Вэксинес Энд Дайэгностикс, Инк. Антибактериальные агенты
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
RU2369636C2 (ru) 2003-05-23 2009-10-10 Уайт Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
EP1692318A4 (en) 2003-12-02 2008-04-02 Genzyme Corp COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
SI2161336T1 (sl) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010003118A1 (en) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
EP2334636A2 (en) 2008-09-19 2011-06-22 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
PL3023438T3 (pl) 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
JP5671545B2 (ja) * 2009-10-13 2015-02-18 ファイザー・インク 抗菌薬として有用なｃ結合ヒドロキサム酸誘導体
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011073845A1 (en) * 2009-12-16 2011-06-23 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
DK2519543T3 (en) 2009-12-29 2016-09-26 Emergent Product Dev Seattle HETERODIMER BINDING PROTEINS AND USE THEREOF
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
CA2817211A1 (en) 2010-11-10 2012-11-15 Ramesh Kasar Hydroxamic acid derivatives and their use in the treatment of bacterial infections
CN104529883A (zh) 2011-03-07 2015-04-22 辉瑞大药厂 可用作抗菌剂的氟吡啶酮衍生物
AU2012238374B2 (en) * 2011-04-08 2015-04-02 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
CN103492368A (zh) * 2011-04-08 2014-01-01 辉瑞大药厂 用作抗菌剂的咪唑、吡唑和噻唑衍生物
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
HUE051954T2 (hu) 2011-11-28 2021-03-29 Merck Patent Gmbh ANTI-PD-L1 ellenanyagok és alkalmazásaik
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections

Also Published As

Publication number Publication date
LT3233843T (lt) 2019-12-10
US9549916B2 (en) 2017-01-24
CO2017005870A2 (es) 2017-10-20
US9815804B2 (en) 2017-11-14
MY195743A (en) 2023-02-08
PE20171044A1 (es) 2017-07-19
CR20170260A (es) 2017-08-21
JP6697466B2 (ja) 2020-05-20
HUE047225T2 (hu) 2020-04-28
US20170088525A1 (en) 2017-03-30
PH12017501019B1 (en) 2017-12-04
IL252373A0 (en) 2017-07-31
UY36448A (es) 2016-07-29
BR112017011422A2 (pt) 2018-04-03
PT3233843T (pt) 2019-11-26
TN2017000207A1 (en) 2018-10-19
PL3233843T3 (pl) 2020-04-30
ES2756300T3 (es) 2020-04-27
ECSP17045737A (es) 2019-02-28
KR20170094214A (ko) 2017-08-17
CN107001295B (zh) 2021-02-02
HRP20192009T1 (hr) 2020-02-07
ME03546B (me) 2020-07-20
CY1122305T1 (el) 2021-01-27
DK3233843T3 (da) 2019-11-18
EA032138B1 (ru) 2019-04-30
EA201791353A1 (ru) 2017-10-31
CL2017001460A1 (es) 2017-12-22
US10029994B2 (en) 2018-07-24
AU2015365455B2 (en) 2019-01-17
CN107001295A (zh) 2017-08-01
EP3233843A1 (en) 2017-10-25
UA121225C2 (uk) 2020-04-27
SG11201704053WA (en) 2017-06-29
WO2016097995A1 (en) 2016-06-23
CA2969803A1 (en) 2016-06-23
SI3233843T1 (sl) 2019-12-31
CU24443B1 (es) 2019-10-04
GT201700132A (es) 2019-10-10
US20180030004A1 (en) 2018-02-01
SV2017005462A (es) 2018-04-04
EP3233843B1 (en) 2019-10-16
JO3818B1 (ar) 2021-01-31
PH12017501019A1 (en) 2017-12-04
TWI693215B (zh) 2020-05-11
JP2018500333A (ja) 2018-01-11
MX2017007980A (es) 2017-09-29
TW201629024A (zh) 2016-08-16
AU2015365455A1 (en) 2017-06-08
AR107428A1 (es) 2018-05-02
IL252373B (en) 2019-11-28
RS59507B1 (sr) 2019-12-31
MA41185B1 (fr) 2019-12-31
US20160166548A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
CU20170084A7 (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
SV2016005274A (es) Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
EA201391072A1 (ru) Производные фтор-пиридинона, полезные в качестве антибактериальных агентов
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
MX2013011526A (es) Derivados de isoxazol utiles como agentes antibacteriales .
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
CU24562B1 (es) Inhibidores de beta-lactamasa útiles contra infecciones bacterianas
UY36043A (es) COMPUESTOS ORGÁNICOS DE MONOBACbTAM PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS
CR20160412A (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas